Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy
- PMID: 33004476
- PMCID: PMC8396076
- DOI: 10.1158/2159-8290.CD-20-1087
Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy
Abstract
In this issue of Cancer Discovery, Pennycuick and colleagues comprehensively evaluate the immune contexture of progressive and regressive lesions in squamous pulmonary premalignancy. The authors dissect the molecular features of these lesions and the potential pathways of immune escape operative in progression to invasive cancer.See related article by Pennycuick et al., p. 1489.
©2020 American Association for Cancer Research.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
Steven M. Dubinett is an advisory board member for EarlyDx Inc., T-Cure Bioscience Inc., LungLife AI, and the Johnson and Johnson Lung Cancer Initiative
Figures

Comment on
-
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.Cancer Discov. 2020 Oct;10(10):1489-1499. doi: 10.1158/2159-8290.CD-19-1366. Epub 2020 Jul 20. Cancer Discov. 2020. PMID: 32690541 Free PMC article.